popup

RECOVERY, 2022 NCT04381936

baricitinib vs. standard of care

COVID 19 all comers

ruxolitinib NOVARTIS, 0

ruxolitinib vs. control

COVID 19 all comers

COV-BARRIER, 2021 NCT04421027

baricitinib vs. placebo

COVID 19 hospitalized

ACTT-2 (Kalil), 2020 NCT04401579

baricitinib vs. placebo

COVID 19 hospitalized

STOP-COVID (Guimarães), 2021 NCT04469114

tofacitinib vs. placebo

COVID 19 hospitalized

Rodriguez-Garcia, 2020 EUPAS34966

baricitinib vs. standard of care

COVID-19 mild to moderate

Cantini, 2020

baricitinib vs. standard of care

COVID-19 mild to moderate

Cantini, 2020

baricitinib vs. standard of care

COVID-19 mild to moderate

Vergis, 2021 NCT04581954

ruxolitinib vs. standard of care

COVID-19 mild to moderate

Murugesan, 2022

tofacitinib vs. standard of care

COVID-19 mild to moderate

COV-BARRIER (critically ill), 2022 NCT04421027

baricitinib vs. placebo

COVID-19 severe or critically

Tziolos, 2021

baricitinib vs. standard of care

COVID-19 severe or critically

RUXCOVID, 0 NCT04362137

ruxolitinib vs. placebo

COVID-19 severe or critically

DEVENT, 0 NCT04377620

ruxolitinib vs. placebo

COVID-19 severe or critically

Cao, 2020

ruxolitinib vs. vitamin C

COVID-19 severe or critically

Singh (TD-0903 10mg), 2021 NCT04402866

TD-0903 10mg vs. placebo

COVID-19 severe or critically

Singh (TD-0903 1mg), 2021 NCT04402866

TD-0903 1mg vs. placebo

COVID-19 severe or critically

Singh (TD-0903 3mg), 2021 NCT04402866

TD-0903 3mg vs. placebo

COVID-19 severe or critically